Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276594 | 0.84 | PRKCZ (0.33) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24295 | 0.76 | IMPDH2 (0.41) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27617892 | 0.74 | EGFR (0.35) | — | |
| SCHEMBL18987 | 0.73 | CYP1A2 (0.39) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25273 | 0.73 | CLK1 (0.40) | KDM4EIMPDH2HTT | |
| SCHEMBL449540 | 0.71 | KDM4E (0.34) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27606375 | 0.71 | CYP1A2 (0.38) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14716557 | 0.70 | IMPDH2 (0.43) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5657919 | 0.70 | CHUK (0.36) | LMNAKDM4EIMPDH2PRKCZHTT | |
| SCHEMBL2355470 | 0.70 | CYP1A2 (0.41) | CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2746281-B1 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-04-26 | — | — | EP | claimed |
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | claimed |
| US-20150152104-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-04 | — | — | US | claimed |
| US-8981101-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2015-03-17 | — | — | US | claimed |
| EP-2746281-A2 | 7-azaindole derivatives | Merck Patent GmbH (DE) | 2014-06-25 | — | — | EP | claimed |
| EP-2670748-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2013-12-11 | — | — | EP | claimed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | claimed |
| WO-2012104007-A2 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-08-09 | — | — | WO | claimed |
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | CARLSSON JENS (SE) | 2024-06-27 | — | — | US | disclosed |
| CN-117751105-A | Substituted hydantoin compounds, process for their preparation and their use in the treatment and/or prophylaxis of coronavirus diseases | J·卡尔松 | 2024-03-22 | — | — | CN | disclosed |
| EP-4329883-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | Carlsson, Jens (SE) | 2024-03-06 | — | — | EP | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060069140-A1 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | LMNA 4738/4885CYP1A2 434/4885CYP3A4 337/4885 |
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | LMNA 1464/4885CYP1A2 4780/4885CYP3A4 4794/4885 |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | LMNA 3373/4885CYP1A2 2325/4885CYP3A4 2739/4885 |
| US-20150152104-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | LMNA 3373/4885CYP1A2 2325/4885CYP3A4 2739/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | LMNA 2077/4885CYP1A2 4134/4885CYP3A4 3034/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | LMNA 2077/4885CYP1A2 4134/4885CYP3A4 3034/4885 |
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | FURIN, ACE, PEPD | LMNA 422/4885CYP1A2 216/4885CYP3A4 215/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | LMNA 3237/4885CYP1A2 1934/4885CYP3A4 1405/4885 |
| US-20060069140-A1 | Pyrazolone compounds and thrombopoietin receptor activator | MPL, PDGFRA, THPO | LMNA 2707/4885CYP1A2 1016/4885CYP3A4 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.